Global Cancer Incidence and Screening
Global Cancer Incidence and Screening is a research topic within Oncology. Science Explorer counts 43k research works in it since 1950. 15.7% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the global patterns of cancer incidence, mortality, and survival, with an emphasis on epidemiological research, health disparities, and the impact of various screening and preventive services. It covers a wide range of topics including breast cancer screening, risk factors for cancer, and the effectiveness of different healthcare interventions.
- Cancer Incidence
- Mortality Rates
- Global Surveillance
- Breast Cancer Screening
- Epidemiological Research
- Health Disparities
- Cancer Survival
- Risk Factors
- Preventive Services
- Population-Based Study
- Research works
- 43k fractional, since 1950
- In the world top 10%
- 6.8k per year above
- Top-10% rate
- 15.7% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +35% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Global Cancer Incidence and Screening research?
By volume, the United States and the United Kingdom publish the most (3.6k and 593 works in 2022–2025).
By volume, 2022–2025
- 1 United States 3.6k works
- 2 United Kingdom 593 works
- 3 China 515 works
- 4 India 371 works
- 5 Australia 323 works
- 6 Canada 292 works
- 7 Brazil 284 works
- 8 France 179 works
- 9 Iran 176 works
- 10 Italy 158 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Global Cancer Incidence and Screening research?
By volume in 2022–2025, University of North Carolina at Chapel Hill publishes the most Global Cancer Incidence and Screening research, followed by The University of Texas MD Anderson Cancer Center and Harvard University.
By volume, 2022–2025
- 1 University of North Carolina at Chapel Hill United States 104 works
- 2 The University of Texas MD Anderson Cancer Center United States 48 works
- 3 Harvard University United States 45 works
- 4 National Cancer Institute United States 41 works
- 5 University of Michigan United States 39 works
- 6 American Cancer Society United States 39 works
- 7 Chinese Academy of Medical Sciences & Peking Union Medical College China 38 works
- 8 The University of Sydney Australia 35 works
- 9 Memorial Sloan Kettering Cancer Center United States 34 works
- 10 University of California, San Francisco United States 33 works
Who are the leading researchers in Global Cancer Incidence and Screening?
The most-cited researchers publishing on Global Cancer Incidence and Screening include Ali H. Mokdad, Yousef Khader and Walter C. Willett.
- 1 Ali H. Mokdad 10k citations
- 2 Yousef Khader 7.7k citations
- 3 Walter C. Willett 6.8k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Global Cancer Incidence and Screening research done?
The largest centres of Global Cancer Incidence and Screening research in 2022–2025 are London (United Kingdom), New York (United States), Boston (United States) and Philadelphia (United States).
Largest cities, 2022–2025
- 1 London United Kingdom 186 works
- 2 New York United States 181 works
- 3 Boston United States 146 works
- 4 Philadelphia United States 119 works
- 5 Chapel Hill United States 108 works
- 6 Atlanta United States 100 works
- 7 Houston United States 99 works
- 8 Beijing China 95 works
- 9 Los Angeles United States 93 works
- 10 Sydney Australia 86 works
Where is the best place to study Global Cancer Incidence and Screening?
Among universities, judged by research, Chinese Academy of Medical Sciences & Peking Union Medical College, London School of Hygiene & Tropical Medicine and Addis Ababa University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Chinese Academy of Medical Sciences & Peking Union Medical College China | 67.4 | 46.6% | 4.2× | 38 | +260.1% |
| 2 | London School of Hygiene & Tropical Medicine United Kingdom | 56.6 | 23.0% | 9.3× | 13 | +67.7% |
| 3 | Addis Ababa University Ethiopia | 54.8 | 21.9% | 7.3× | 16 | +451.2% |
| 4 | University of Gondar Ethiopia | 54.0 | 34.1% | 8.9× | 12 | — |
| 5 | Medical College of Wisconsin United States | 49.5 | 13.9% | 7.7× | 18 | +289.0% |
| 6 | Karolinska Institutet Sweden | 47.5 | 26.5% | 5.0× | 20 | +43.5% |
| 7 | University of North Carolina at Chapel Hill United States | 47.0 | 6.1% | 6.6× | 104 | +73.7% |
| 8 | Augusta University United States | 46.4 | 11.5% | 8.5× | 10 | +238.9% |
| 9 | University of Alabama at Birmingham United States | 44.8 | 14.9% | 7.4× | 33 | +43.6% |
| 10 | Icahn School of Medicine at Mount Sinai United States | 44.2 | 15.2% | 6.6× | 30 | +63.3% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Global Cancer Incidence and Screening research growing?
Output in 2018–2022 was 35% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Global Cancer Incidence and Screening.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.